Global adoption SalivaDirect has achieved international validation in 15+ countries and a nationwide footprint with over 7 million tests across more than 200 CLIA laboratories, indicating a scalable model that can attract partners seeking decentralized, accessible testing solutions.

Nonprofit positioning As a nonprofit spinout with a mission to promote equitable respiratory pathogen surveillance, SalivaDirect can appeal to public health consortiums, government programs, and grant-funded initiatives seeking mission-aligned vendors with proven impact and low-cost offerings.

Cost-effective science Low-cost, open-source diagnostic concepts combined with a robust testing network position SalivaDirect as a compelling partner for budget-conscious institutions and health systems aiming to expand surveillance without significant capital expenditure.

Digital presence A lean tech stack (Squarespace, analytics, tag management) suggests rapid go-to-market capabilities and potential for enhanced data partnerships, digital engagement, and co-branded outreach with sponsors or collaborators.

Growth opportunities With a small internal team and a growing international validation profile, there is opportunity to upsell additional testing services, expand laboratory partnerships, and pursue contracts with healthcare providers, academic institutions, and public health agencies seeking scalable saliva-based diagnostics.